2 withdrawn, 1 unknown. 3 Phase 2, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 3 | Withdrawn 2, Unknown 1 |
| Phase 3 | 1 | Withdrawn 1 |
Follow oplunofusp: new trials by email Literature Review of oplunofusp trials Research Report on oplunofusp
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| DAS181 for STOP COVID-19 DAS181, Placebo - COVID-19 | Phase 2 / Phase 3 | Withdrawn | Ansun Biopharma, Inc. | 2020-07-25 | 2020-08-11 | |
| DAS181 for Patients With Severe Hospitalized Flu and SAD-RVs (COVID-19) DAS181, Placebo - Influenza Infection, SAD-RV Infection and COVID-19 | Phase 2 | Unknown | Ansun Biopharma, Inc. | 280 | 2020-07-01 | 2020-07-09 |
| DAS181 in Patients With Parainfluenza DAS181, Placebo - Parainfluenza Infection | Phase 2 | Withdrawn | National Institute of Allergy and Infectious Diseases (NIAID) | 2011-07-14 | 2019-12-17 |
COVID-19 (2) · Coronavirus Infections (1) · Fever (1) · Hypoxia (1) · Infections (1) · Influenza, Human (1) · Paramyxoviridae Infections (1) · Respiratory Tract Diseases (1)
Ansun Biopharma, Inc. (2) · National Institute of Allergy and Infectious Diseases (NIAID) (1)
China (1) · Italy (1)
Jennifer Ho, MD, PhD (2) · Richard T Davey, M.D. (1)